RWD178 Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T-Cell (CAR T) and Monoclonal Antibodies (MAB) Therapies

Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2728
https://www.valueinhealthjournal.com/article/S1098-3015(23)02918-2/fulltext
Title : RWD178 Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T-Cell (CAR T) and Monoclonal Antibodies (MAB) Therapies
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02918-2&doi=10.1016/j.jval.2023.03.2728
First page :
Section Title :
Open access? : No
Section Order : 11528
Categories :
Tags :
Regions :
ViH Article Tags :